A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
Clinical trial NCT04666740 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04666740
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-18
- Primary completion
- 2027-01-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.